Clinical Advancements
He we try and keep up to date on the treatments newly available or in the pipeline.
September 2025 - Benmelstobart plus anlotinib improved progression-free survival compared with sunitinib among patients with previously untreated, advanced clear-cell renal cell carcinoma. These findings suggest the potential of benmelstobart plus anlotinib as a treatment option for this population.
August 2025 - 3D-printed kidney tumors show potential for more targeted treatment.
July 2025 - Cancer vaccines have always chased a moving target, every tutor is genetically unique. But what if we stop chasing specific mutations and start reprogramming the immune system itself?
13th June 2025, researchers at Johns Hopkins Medicine found that fragments of tumour DNA can appear in the bloodstream up to three years before a cancer diagnosis, offering a potentially revolutionary window for early detection and treatment.
This article from April 2025 explains how the subcutaneous formulation of nivolumab can be given as a 3–5-minute injection instead of the 30- or 60-minute intravenous (IV) infusion.
This article from March 2025, explains how a simple urine test could detect a recurrence of kidney cancer, halving post-op scans.
This article from February 2025 by Ojas Rajkumar and Professor Lennard Lee, covers the latest exciting vaccine developments in the UK.
​